Program
abrocitinib
Also written as “PF-04965842”, “PF-04965842 200 mg” and “PF-04965842 100 mg”.
Its studies are mostly in Dermatitis, Atopic · Dermatitis · Eczema · Renal Insufficiency · Psoriasis, led by Pfizer.
Furthest: phase 3, since Nov 17, 201730 company-led studies, 3 open or runningNext primary completion: May 2, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 303 open or running | phase 3since Nov 17, 2017 | Apr 15, 2013 | May 2, 2027phase 3 · NCT06807268 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Apr 15, 2013.
- Aug 8, 20183 phase 1 studiesNCT03626415, NCT03634345, NCT03637790
- Sep 4, 20182 phase 1 studiesNCT03660241, NCT03662516
- Oct 24, 2018Phase 3 study in DermatitisNCT03720470 · 838 enrolled · United States, Australia, Bulgaria and more
- Nov 13, 2018Phase 1 study in HealthyNCT03742336 · 20 enrolled · Belgium
- Jan 4, 2019Phase 3 study in Dermatitis, AtopicNCT03796676 · 287 enrolled · United States, Australia, China and more
- Jan 4, 20192 phase 1 studiesNCT03796182, NCT03806101
- Mar 22, 2019Phase 2 study in Dermatitis, AtopicNCT03915496 · 46 enrolled · United States, Canada
- Sep 3, 2019Phase 1 study in HEALTHYNCT04099563 · 13 enrolled · China
- Mar 27, 2020Phase 3 study in Dermatitis, AtopicNCT04345367 · 727 enrolled · United States, Australia, Bulgaria and more
- May 21, 2021Phase 1 study in Dermatitis, AtopicNCT04903093 · 19 enrolled · United States
- Sep 24, 2021Phase 1 study in Healthy ParticipantsNCT05067439 · 26 enrolled · United States
- May 11, 2022Phase 3 study in Dermatitis, AtopicNCT05375929 · 200 enrolled · India
- Jan 29, 20252 phase 3 studiesNCT06807281, NCT06807268
- Sep 11, 2026Phase 3 study in Dermatitis, AtopicNCT07823595 · 90 planned
Ahead
- May 2, 2027Primary completion: phase 3 study in EczemaNCT06807268
- Apr 10, 2029Primary completion: phase 3 study in Dermatitis, AtopicNCT07823595
- Feb 22, 2032Primary completion: phase 3 study in Dermatitis, AtopicNCT06807281
TargetBeta
JAK1 →read by rule
“Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule
Other programs on JAK1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| baricitinibrule | Eli Lilly | phase 4 | 59 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| ivarmacitinibrule | Jiangsu HengRui Medicine | phase 3 | 25 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| momelotinibrule | GlaxoSmithKline | phase 3 | 17 |
| golidocitinibrule | Dizal Pharmaceuticals | phase 3 | 10 |
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07823595Dermatitis, Atopic | 3 | Not yet recruiting | Apr 10, 2029 | 90 |
| NCT06807281Dermatitis, Atopic · United States, China, Hungary and more | 3 | Recruiting | Feb 22, 2032 | 450 |
| NCT06807268Eczema · United States, China, Germany and more | 3 | Active, not recruiting | May 2, 2027 | 151 |
| NCT05375929Dermatitis, Atopic · India | 3 | Completed | Jun 9, 2023 | 200 |
| NCT05067439Healthy Participants · United States | 1 | Completed | Feb 26, 2022 | 26 |
| NCT04903093Dermatitis, Atopic · United States | 1 | Completed | Oct 26, 2021 | 19 |
| NCT04345367Dermatitis, Atopic · United States, Australia, Bulgaria and more | 3 | Completed | Jul 13, 2021 | 727 |
| NCT04099563HEALTHY · China | 1 | Completed | Nov 9, 2019 | 13 |
| NCT03915496Dermatitis, Atopic · United States, Canada | 2 | Completed | Nov 16, 2021 | 46 |
| NCT03806101Healthy · Belgium | 1 | Completed | Mar 15, 2019 | 12 |
| NCT03796676Dermatitis, Atopic · United States, Australia, China and more | 3 | Completed | Apr 8, 2020 | 287 |
| NCT03796182Dermatitis, Atopic · Belgium | 1 | Completed | Feb 13, 2019 | 12 |
| NCT03742336Healthy · Belgium | 1 | Completed | Feb 18, 2019 | 20 |
| NCT03720470Dermatitis · United States, Australia, Bulgaria and more | 3 | Completed | Dec 27, 2019 | 838 |
| NCT03662516Healthy Females · United States | 1 | Completed | Jan 19, 2019 | 17 |
| NCT03660241Renal Insufficiency · United States, Belgium | 1 | Completed | Nov 5, 2019 | 23 |
| NCT03637790Healthy · Belgium | 1 | Completed | Dec 14, 2018 | 12 |
| NCT03634345Dermatitis, Atopic · Belgium | 1 | Completed | Dec 13, 2018 | 24 |
| NCT03626415Hepatic Impairment · United States | 1 | Completed | Apr 30, 2019 | 24 |
| NCT03647670Phase 1 · Belgium | 1 | Completed | Oct 16, 2018 | 25 |
| NCT03575871Dermatitis, Atopic · United States, Australia, Bulgaria and more | 3 | Completed | Aug 13, 2019 | 391 |
| NCT03627767Dermatitis · United States, Argentina, Belgium and more | 3 | Completed | Sep 2, 2020 | 1,235 |
| NCT03386279Healthy Volunteers · Belgium | 1 | Completed | Oct 1, 2018 | 36 |
| NCT03422822Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Completed | Dec 22, 2025 | 3,166 |
| NCT03349060Dermatitis, Atopic · United States, Australia, Canada and more | 3 | Completed | Mar 26, 2019 | 387 |
| NCT03250039Healthy · Netherlands | 1 | Completed | Sep 15, 2017 | 6 |
| NCT02780167Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Completed | Mar 2017 | 269 |
| NCT02201524Plaque, Amyloid · United States, Canada | 2 | Terminated | Sep 2015 | 59 |
| NCT02163161Fasting · Belgium | 1 | Completed | Aug 2014 | 12 |
| NCT01835197Healthy · United States | 1 | Completed | Jun 2014 | 79 |
How it is read
Names in the registry
- “PF-04965842”, 26 entries
- “PF-04965842 200 mg”, 5 entries
- “PF-04965842 100 mg”, 5 entries
- “Abrocitinib”, 4 entries
- “Abrocitinib 200 mg”, 4 entries
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 13 studies
- Dermatitis, 2 studies
- Eczema, 1 study
- Renal Insufficiency, 1 study
- Psoriasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.